• English
  • 简体中文
Login Register
Current Location: Home > Drug Registration and Acceptance subscription Help
-
-
-
Visualized Analysis Export Evaluation Conclusion Evaluation Progress
Acceptance No. Drug Name Active Ingredient Dosage Form Classification Submission Acceptance Date Manufacturers Manufacturers Review Status Status Date View
CYSB2300099 注射用重组人II型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(原7) Supplementary Application 2023-05-22 Hisun Biopharmaceutical Co Ltd view
CYSB1900326 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products Supplementary Application 2019-09-19 上海赛金生物医药有限公司 Shanghai Celgen Bio-Pharmaceutical Co Ltd Certificate Issued 2019-12-13 view
CXSS1900024 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(15) New Drug Application 2019-05-21 齐鲁制药有限公司 QILU Pharmaceutical Co Ltd In Review 2019-05-20 view
CYSB1500313 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products Supplementary Application 2015-11-30 浙江海正药业股份有限公司 Zhejiang Hisun Pharmaceutical Co Ltd Certificate Issued 2018-02-27 view
CXSB1400017 注射用重组人II型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products Supplementary Application 2014-12-26 上海赛金生物医药有限公司 Shanghai Celgen Bio-Pharmaceutical Co Ltd Certificate Issued 2016-10-11 view
CXSB1300016 注射用重组人II型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products Supplementary Application 2013-09-22 浙江海正药业股份有限公司 Zhejiang Hisun Pharmaceutical Co Ltd Certificate Issued 2015-05-04 view
CXSB1300017 注射用重组人II型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products Supplementary Application 2013-09-22 浙江海正药业股份有限公司 Zhejiang Hisun Pharmaceutical Co Ltd Certificate Issued 2015-05-04 view
CXSS1300017 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(7) New Drug Application 2013-07-12 浙江海正药业股份有限公司 Zhejiang Hisun Pharmaceutical Co Ltd Certificate Issued 2015-04-22 view
CXSS1300016 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(7) New Drug Application 2013-07-12 浙江海正药业股份有限公司 Zhejiang Hisun Pharmaceutical Co Ltd Certificate Issued 2015-04-22 view
CYSB1300123 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products Supplementary Application 2013-06-03 上海赛金生物医药有限公司 Shanghai Celgen Bio-Pharmaceutical Co Ltd Certificate Issued 2014-01-03 view
CXSL1200038 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(15) New Drug Application 2012-08-16 苏州金盟生物技术有限公司 Suzhou Genemen Biotech Co Ltd Certificate Issued 2015-01-15 view
CXSL1100067 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(15) New Drug Application 2012-03-07 北京双鹭药业股份有限公司 Beijing SL Pharmaceutical Co Ltd Certificate Issued 2014-11-21 view
CXSL1100066 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(15) New Drug Application 2011-12-08 齐鲁制药有限公司 QILU Pharmaceutical Co Ltd Certificate Issued 2013-09-13 view
CXSS1000009 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(7) New Drug Application 2010-10-12 浙江海正药业股份有限公司 Zhejiang Hisun Pharmaceutical Co Ltd Certificate Issued 2012-05-28 view
CYSB0900203 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products Supplementary Application 2010-01-07 上海中信国健药业有限公司 Sunshine Guojian Pharmaceutical(Shanghai) Co Ltd Certificate Issued 2011-04-12 view
CYSB0900204 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products Supplementary Application 2010-01-07 上海中信国健药业有限公司 Sunshine Guojian Pharmaceutical(Shanghai) Co Ltd Certificate Issued 2011-04-12 view
CYSB0900259 注射用重组人II型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products Supplementary Application 2009-10-10 浙江海正药业股份有限公司 Zhejiang Hisun Pharmaceutical Co Ltd Certificate Issued 2010-04-01 view
CXSS0700068 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(7) New Drug Application 2007-12-07 上海赛金生物医药有限公司 Shanghai Celgen Bio-Pharmaceutical Co Ltd Certificate Issued 2011-04-14 view
CXSS0600037 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(7) New Drug Application 2006-03-13 上海中信国健药业有限公司 Sunshine Guojian Pharmaceutical(Shanghai) Co Ltd Certificate Issued 2007-05-21 view
CXSS0600036 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 Lyophilized Biological Products(7) New Drug Application 2006-03-13 上海中信国健药业有限公司 Sunshine Guojian Pharmaceutical(Shanghai) Co Ltd Certificate Issued 2007-05-21 view